{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:27:58Z","timestamp":1794414478865,"version":"4.9.1"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:sec id=\"ab-soi260059-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Relapse risk and benefit of adjuvant chemotherapy after resection of appendiceal adenocarcinoma (AA) are uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-soi260059-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To identify clinicopathologic and genomic factors associated with relapse and assess efficacy of adjuvant chemotherapy in localized AA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-soi260059-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This retrospective cohort study (January 2000 through February 2024; median follow-up, 62.6 months) used Kaplan-Meier and Cox proportional hazards modeling. It took place at the University of Texas MD (UT MD) Anderson Cancer Center with validation from Memorial Sloan Kettering Cancer Center (MSKCC). Participants included a complete localized cohort of 439 patients with stage I to III AA from UT MD Anderson, of whom 202 underwent surgery at UT MD Anderson and also included a validation cohort of 128 patients with stage II AA from MSKCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-soi260059-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Surgical resection with or without adjuvant chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-soi260059-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Rate of recurrence, recurrence-free survival (RFS), and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-soi260059-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 439 patients with localized AA (median age, 56.5 [IQR, 22.2-83.7] years; 50% female and 50% male) managed at MD Anderson between January 2000 and February 2024. Of 202 MDA surgical patients, 19 (9.4%) had a relapse including 9 (6%) patients with stage II and 8 (19.5%) of patients stage III disease. Five-year OS was 95.7% without vs 77.2% with relapse (hazard ratio [HR], 5.50; 95% CI, 3.07-9.83;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). Relative to goblet cell tumors, mucinous (HR, 5.60; 95% CI, 2.1-15;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001) and enteric-type (HR, 6.60; 95% CI, 2.9-15;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001) histologies were independently associated with relapse, as was pathologic T4 (HR, 3.30; 95% CI, 1.9-5.7;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). Importantly, poor differentiation, perforation, lymphovascular invasion, and perineural invasion, known risk factors in colorectal cancer, were not significantly associated with relapse. For the complete localized cohort, adjuvant chemotherapy was not associated with improved RFS (univariate HR, 2.06; 95% CI, 1.36-3.13;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.001 and multivariable HR, 0.98; 95% CI, 0.43-2.28;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.90) or OS (univariate HR, 1.80; 95% CI, 1.0-3.2;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.04 and multivariable HR, 0.71; 95% CI, 0.24-2.1;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.53).\n                      <jats:italic toggle=\"yes\">TP53<\/jats:italic>\n                      mutation in goblet cell tumors (HR, 6.93; 95% CI, 1.50-31.00;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.01) and\n                      <jats:italic toggle=\"yes\">GNAS<\/jats:italic>\n                      mutation in nongoblet tumors (HR, 17.0; 95% CI, 3.09-93.3;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.001) were associated with greater risk of relapse.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-soi260059-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>These results demonstrate that relapse after resection of localized AA is uncommon. Molecular profiling and histopathologic subtype refine risk. Adjuvant chemotherapy were not associated with benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamasurg.2026.4000","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:00:19Z","timestamp":1788966019000},"page":"1165","source":"Crossref","is-referenced-by-count":0,"title":["Risk of Relapse and Efficacy of Adjuvant Chemotherapy in Localized Appendiceal Adenocarcinoma"],"prefix":"10.1001","volume":"161","author":[{"given":"Sacha","family":"El Khoury","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad M.","family":"Fanaeian","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Yousef","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Yousef","sequence":"additional","affiliation":[{"name":"University of New Mexico Hospital, Albuquerque"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saikat","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emaan","family":"Haque","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Hornstein","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa W.","family":"Taggart","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Pathology\u2013Lab Medicine, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Chin","family":"Foo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Division of Pathology\u2013Lab Medicine, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarett","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Aguirre","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett","family":"Nash","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Gowda","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Karagkounis","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cercek","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efsevia","family":"Vakiani","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Koehne","family":"de Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen A.","family":"Beaty","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Pattalachinti","sequence":"additional","affiliation":[{"name":"UT Health San Antonio, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micheal","family":"Overmann","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Scally","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Mansfield","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"White","sequence":"additional","affiliation":[{"name":"Department of Colon and Rectal Surgery, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Helmink","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith F.","family":"Fournier","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Foote","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Paul","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"soi260059r1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/BF02236899","article-title":"Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies.","volume":"41","author":"Connor","year":"1998","journal-title":"Dis Colon Rectum"},{"issue":"12","key":"soi260059r2","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1002\/cncr.10589","article-title":"Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998.","volume":"94","author":"McCusker","year":"2002","journal-title":"Cancer"},{"issue":"4","key":"soi260059r3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1055\/s-0035-1564433","article-title":"Management of appendix cancer.","volume":"28","author":"Kelly","year":"2015","journal-title":"Clin Colon Rectal Surg"},{"issue":"1","key":"soi260059r4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1470-2045(05)70539-8","article-title":"New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?","volume":"7","author":"Sugarbaker","year":"2006","journal-title":"Lancet Oncol"},{"issue":"10","key":"soi260059r6","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1158\/1078-0432.CCR-18-3388","article-title":"Molecular profiling of appendiceal adenocarcinoma and comparison with right-sided and left-sided colorectal cancer.","volume":"25","author":"Tokunaga","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"8","key":"soi260059r7","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1200\/JCO.22.01392","article-title":"Molecular classification of appendiceal adenocarcinoma.","volume":"41","author":"Foote","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"soi260059r8","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1158\/1078-0432.CCR-22-3956","article-title":"The Impact of germline alterations in appendiceal adenocarcinoma.","volume":"29","author":"Foote","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"8","key":"soi260059r9","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41416-020-1015-3","article-title":"Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer.","volume":"123","author":"Raghav","year":"2020","journal-title":"Br J Cancer"},{"key":"soi260059r10","first-page":"2","article-title":"Genomic landscape of appendiceal neoplasms.","volume":"2","author":"Ang","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"35","key":"soi260059r11","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","article-title":"Adjuvant fluorouracil, leucovorin, and oxaliplatin in Stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study.","volume":"33","author":"Andr\u00e9","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"soi260059r12","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1200\/JCO.2008.19.5362","article-title":"Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.","volume":"27","author":"Sargent","year":"2009","journal-title":"J Clin Oncol"},{"issue":"23","key":"soi260059r13","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"N Engl J Med"},{"issue":"13","key":"soi260059r14","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for Stage III colon cancer.","volume":"378","author":"Grothey","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"soi260059r15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1200\/JOP.2016.017210","article-title":"Adjuvant chemotherapy for stage II colon cancer: a clinical dilemma.","volume":"13","author":"Kannarkatt","year":"2017","journal-title":"J Oncol Pract"},{"issue":"27","key":"soi260059r16","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.2012.42.5645","article-title":"Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.","volume":"30","author":"Tournigand","year":"2012","journal-title":"J Clin Oncol"},{"key":"soi260059r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100329","article-title":"Impact of high-risk features for stage II adenocarcinoma of the appendix.","volume":"27","author":"Akce","year":"2021","journal-title":"Cancer Treat Res Commun"},{"issue":"2","key":"soi260059r18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1245\/s10434-024-16366-7","article-title":"Predictors of recurrence in nonmetastatic appendiceal epithelial cancers: an updated single-center experience over 25 years.","volume":"32","author":"Aguirre","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"soi260059r19","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/his.13324","article-title":"The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei.","volume":"71","author":"Carr","year":"2017","journal-title":"Histopathology"},{"issue":"2","key":"soi260059r20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system.","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"issue":"1","key":"soi260059r21","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s00384-023-04559-7","article-title":"Prognostic factors in patients with high-risk stage II colon cancer after curative resection: a post hoc analysis of the JFMC46-1201 trial.","volume":"38","author":"Sugimoto","year":"2023","journal-title":"Int J Colorectal Dis"},{"issue":"12","key":"soi260059r22","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1097\/PAS.0000000000001570","article-title":"Optimal criteria for G3 (poorly differentiated) stage II colon cancer: prospective validation in a randomized controlled study (SACURA Trial).","volume":"44","author":"Ueno","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"soi260059r23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/20009666.2017.1407210","article-title":"Factors associated with short recurrence-free survival in completely resected colon cancer.","volume":"7","author":"Alnimer","year":"2017","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"soi260059r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.soda.2022.100054","article-title":"The role of high-risk features in stage II colon cancer after surgical treatment*.","volume":"7","author":"Bernardo Lynn","year":"2022","journal-title":"Surg Open Dig Adv"},{"issue":"28","key":"soi260059r25","doi-asserted-by":"publisher","first-page":"46565","DOI":"10.18632\/oncotarget.15425","article-title":"Lymphovascular invasion is a high risk factor for stage I\/II colorectal cancer: a systematic review and meta-analysis.","volume":"8","author":"Yuan","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"soi260059r26","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1245\/s10434-010-0982-7","article-title":"Prognostic value of perineural invasion in patients with stage II colorectal cancer.","volume":"17","author":"Huh","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"soi260059r27","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3393\/ac.2017.33.6.232","article-title":"Clinical significance of signet-ring-cell colorectal cancer as a prognostic factor.","volume":"33","author":"Yun","year":"2017","journal-title":"Ann Coloproctol"},{"key":"soi260059r28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00302","article-title":"Genomic landscape of appendiceal neoplasms.","volume":"2","author":"Ang","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"soi260059r29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003109","article-title":"Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei.","volume":"9","author":"Flatmark","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"32","key":"soi260059r30","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1200\/JCO.24.00186","article-title":"Molecular and clinicopathologic impact of GNAS variants across solid tumors.","volume":"42","author":"Johannet","year":"2024","journal-title":"J Clin Oncol"},{"key":"soi260059r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2024.102034","article-title":"Surgical outcomes and predictors of overall survival of stage I-III appendiceal adenocarcinoma: retrospective cohort analysis of the national cancer database.","volume":"52","author":"Emile","year":"2024","journal-title":"Surg Oncol"},{"key":"soi260059r32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.suronc.2020.12.003","article-title":"Is adjuvant chemotherapy beneficial for stage II-III goblet cell carcinoid\/goblet cell adenocarcinoma of the appendix?","volume":"36","author":"Zakka","year":"2021","journal-title":"Surg Oncol"},{"key":"soi260059r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2020.02.012","article-title":"Appendiceal tumours and pseudomyxoma peritonei: literature review with PSOGI\/EURACAN clinical practice guidelines for diagnosis and treatment.","author":"Govaerts","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"soi260059r34","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/jso.23547","article-title":"Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.","volume":"109","author":"Blackham","year":"2014","journal-title":"J Surg Oncol"},{"issue":"10","key":"soi260059r35","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1002\/cam4.3009","article-title":"Impact of adjuvant chemotherapy on outcomes in appendiceal cancer.","volume":"9","author":"Kolla","year":"2020","journal-title":"Cancer Med"},{"issue":"6","key":"soi260059r37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.16161","article-title":"Efficacy of systemic chemotherapy in patients with low-grade mucinous appendiceal adenocarcinoma: a randomized crossover trial.","volume":"6","author":"Shen","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"2","key":"soi260059r38","doi-asserted-by":"publisher","first-page":"e240260","DOI":"10.1001\/jamanetworkopen.2024.0260","article-title":"Serum tumor markers and outcomes in patients with appendiceal adenocarcinoma.","volume":"7","author":"Yousef","year":"2024","journal-title":"JAMA Netw Open"},{"key":"soi260059r5","author":"Benson","year":"2023"},{"key":"soi260059r36","unstructured":"Radiology ACo. ACR appropriateness criteria staging and disease monitoring of colon cancer and appendiceal cancer. Accessed August 3, 2026. https:\/\/acsearch.acr.org\/docs\/69408\/Narrative"}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/articlepdf\/2853953\/jamasurgery_el_khoury_2026_oi_260059_1794242249.7928.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:01:47Z","timestamp":1794412907000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2853953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,1]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2026.4000","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11,1]]}}}